Table 1 HVTN current and future phase 1 and discovery medicine clinical trials for investigation of HIV vaccine candidates for generation of broad neutralizing antibodies or T cell responses.
Trial (NCT number) | Immunogen (platform) | Adjuvant(s) | Target epitope(s) |
|---|---|---|---|
HVTN 144 (NCT06033209) | N332-GT5 gp140 (Protein) | SMNP | V3 glycan |
HVTN 300 (NCT04915768) | CH505 TF chTrimer (protein) | 3M-052-AF +/- Alum, Empty LNP | CD4bs, V2 apex, V3 glycan |
HVTN 301 (NCT05471076) | 426 c.Mod.Core-C4b (protein) | 3M-052-AF + Alum | CD4bs |
HVTN 302(NCT05217641) | ・BG505 MD39.3 trimer soluble (mRNA) ・BG505 MD39.3 gp151 trimer membrane-bound (mRNA) ・BG505 MD39.3 gp151 CD4KO trimer (mRNA) | – | V3 complex N-linked glycans, N332-dependent |
HVTN 304(NCT05828095) | ・HIV Env Trimer/IL-12 (INO-6160) (DNA) ・4571 Trimer (BG505) (protein) | 3M-052-AF + Alum | Binding/neutralizing AbsCD4/CD8 responses |
HVTN 305(NCT05781542) | ・sD-NP-GT8/IL-12 (DNA) ・Trimer 4571 (BG505) (protein) | 3M-052-AF + Alum | CD4bs |
HVTN 307(NCT05903339) | V3G CH848 Pr-NP1 (ferritin nanoparticle as protein) V3G CH848 mRNA-Tr2 (mRNA encoding ferritin nanoparticle) | Empty LNP 3M-052-AF | V3 glycan |
HVT 142 (NCT05854381) | VIR 1388 expressing HIV Mfuse1(human CMV vector) | – | Gag, Pol, Nef T cell epitopes |
HVTN 309 | ・CD4BS CH505M5 Pr-1 (RNA) ・CH505 chTrimer (protein) | Empty LNP 3M-052-AF | CD4bs, V2 apex, V3 glycan |
HVTN 310 | HIV-1 Env, HIV-1 Gag and HIV-1 Gag/Pro (mRNA for in vivo VLP generation) | – | CD4bs, V2 apex |
HVTN 312 | Prime: CH505 M5 N197D gp160 (mRNA) Boost: CH505 TF gp160 (mRNA) | – | Early CH235 lineage intermediates ・CH505 TF boost can increase improbable mutations |
